Spero Therapeutics to Present at Investor Conferences in November
Key Highlights
- ➤Spero CEO Esther Rajavelu to join Guggenheim healthcare conference fireside chat November 10
- ➤Management will hold investor meetings at Jefferies Global Healthcare Conference November 18-19
- ➤Lead program SP001 targets IgG4-related disease with potential broader immunological applications
Expert Statements
Esther Rajavelu, President and Chief Executive Officer of Spero Therapeutics
“will participate in a “fireside chat” at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA”
CAMBRIDGE, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company focused on advancing next-generation medicines in immune-mediated diseases, today announced that Esther Rajavelu, President and Chief Executive Officer, will participate in a “fireside chat” at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston, MA. The company's leadership team will be available for one-on-one meetings with investors. The team will also participate in the Jefferies Global Healthcare Conference in London, UK where they will be available for meetings with investors.
Guggenheim 3rd Annual Healthcare Innovation Conference Date: Tuesday, November 10 Time: 10:30 AM ET Location: Boston, MA Webcast Link: click here
Get started
Create a free account to read the full story.